JPWO2021148006A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021148006A5 JPWO2021148006A5 JP2022544309A JP2022544309A JPWO2021148006A5 JP WO2021148006 A5 JPWO2021148006 A5 JP WO2021148006A5 JP 2022544309 A JP2022544309 A JP 2022544309A JP 2022544309 A JP2022544309 A JP 2022544309A JP WO2021148006 A5 JPWO2021148006 A5 JP WO2021148006A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- substitutions
- residue
- heterodimeric protein
- domain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 98
- 235000018102 proteins Nutrition 0.000 claims 48
- 102000004169 proteins and genes Human genes 0.000 claims 48
- 108090000623 proteins and genes Proteins 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 150000001413 amino acids Chemical group 0.000 claims 26
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 15
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 11
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 9
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 230000000873 masking effect Effects 0.000 claims 6
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 102000051957 human ERBB2 Human genes 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020073960 | 2020-01-23 | ||
| CNPCT/CN2020/073960 | 2020-01-23 | ||
| PCT/CN2021/073347 WO2021148006A1 (en) | 2020-01-23 | 2021-01-22 | Heterodimeric proteins with fc mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511376A JP2023511376A (ja) | 2023-03-17 |
| JPWO2021148006A5 true JPWO2021148006A5 (ru) | 2024-01-31 |
Family
ID=76992067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544309A Pending JP2023511376A (ja) | 2020-01-23 | 2021-01-22 | Ｆｃ変異を有するヘテロダイマータンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230124669A1 (ru) |
| EP (1) | EP4093778A1 (ru) |
| JP (1) | JP2023511376A (ru) |
| KR (1) | KR20220145833A (ru) |
| CN (1) | CN115279796A (ru) |
| AU (1) | AU2021210482A1 (ru) |
| BR (1) | BR112022014574A2 (ru) |
| CA (1) | CA3165045A1 (ru) |
| IL (1) | IL294878A (ru) |
| MX (1) | MX2022009101A (ru) |
| TW (1) | TW202140570A (ru) |
| WO (1) | WO2021148006A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023183888A1 (en) * | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2636046C2 (ru) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| JP6320753B2 (ja) * | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| SG10201805291TA (en) * | 2011-10-27 | 2018-08-30 | Genmab As | Production of heterodimeric proteins |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP2951203B1 (en) * | 2013-03-15 | 2019-05-22 | Xencor, Inc. | Heterodimeric proteins |
| CA2929256C (en) * | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| US20160176969A1 (en) * | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| WO2019014912A1 (zh) * | 2017-07-21 | 2019-01-24 | 赵磊 | 一种异二聚体蛋白及其制备方法 |
-
2021
- 2021-01-22 CA CA3165045A patent/CA3165045A1/en active Pending
- 2021-01-22 IL IL294878A patent/IL294878A/en unknown
- 2021-01-22 EP EP21744991.7A patent/EP4093778A1/en active Pending
- 2021-01-22 JP JP2022544309A patent/JP2023511376A/ja active Pending
- 2021-01-22 MX MX2022009101A patent/MX2022009101A/es unknown
- 2021-01-22 BR BR112022014574A patent/BR112022014574A2/pt unknown
- 2021-01-22 KR KR1020227029071A patent/KR20220145833A/ko active Search and Examination
- 2021-01-22 TW TW110102586A patent/TW202140570A/zh unknown
- 2021-01-22 AU AU2021210482A patent/AU2021210482A1/en active Pending
- 2021-01-22 US US17/759,282 patent/US20230124669A1/en active Pending
- 2021-01-22 WO PCT/CN2021/073347 patent/WO2021148006A1/en unknown
- 2021-01-22 CN CN202180021100.0A patent/CN115279796A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11952421B2 (en) | Bispecific antibodies against CD3EPSILON and ROR1 | |
| Kontermann et al. | Bispecific antibodies | |
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| JP2021098732A5 (ru) | ||
| Müller et al. | Bispecific antibodies | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JPWO2019129221A5 (ru) | ||
| AU2010230563A1 (en) | Multispecific antibodies comprising full length antibodies and single chain Fab fragments | |
| AU2012236603A1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| US20220002398A1 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| Wu et al. | Building blocks for bispecific and trispecific antibodies | |
| JPWO2020252264A5 (ru) | ||
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2021507698A5 (ru) | ||
| WO2019199916A1 (en) | Fab-based trispecific antibodies | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022102768A5 (ru) | ||
| JPWO2021064137A5 (ru) | ||
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| JPWO2021148006A5 (ru) | ||
| JPWO2020011964A5 (ru) | ||
| JPWO2020033587A5 (ru) | ||
| JPWO2021076564A5 (ru) | ||
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY |